Vistagen Therapeutics (MEX:VTGN) Total Current Assets: MXN846.51 Mil (As of Mar. 2026)


MEX:VTGN Vistagen Therapeutics Inc MEX:VTGN
40 GF Score
Price MXN10.65
GF Value MXN95.21
! 3 Warning Signs
View Full Analysis

What is Vistagen Therapeutics Total Current Assets?

Vistagen Therapeutics MEX:VTGN 40 Total Current Assets is MXN846.51 Mil as of Mar. 2026. GuruFocus rates MEX:VTGN with a GF Score™ of 40/100 and a GF Value™ of MXN95.21. The stock has 3 warning signs investors should review.

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Vistagen Therapeutics's total current assets for the quarter that ended in Mar. 2026 was MXN846.51 Mil.

Vistagen Therapeutics  (MEX:VTGN) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Vistagen Therapeutics's Liquidation Value for the quarter that ended in Mar. 2026 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=818.739-235.219+0.75 * 0+0.5 * 0
=583.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Total Current Assets Related Terms

Vistagen Therapeutics Total Current Assets Historical Data

* Premium members only.

The historical data trend for Vistagen Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vistagen Therapeutics Total Current Assets Chart

Vistagen Therapeutics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,413.64 315.56 2,002.70 1,679.13 846.51

Vistagen Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,679.13 1,256.21 1,447.98 1,138.77 846.51
MEX:VTGN
40GF Score
Vistagen Therapeutics Inc MEX:VTGN
Total Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vistagen Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Vistagen Therapeutics's Total Current Assets for the fiscal year that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=818.739+0+0+27.77
=846.51

Vistagen Therapeutics's Total Current Assets for the quarter that ended in Mar. 2026 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=818.739+0+0+27.77
=846.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Frequently Asked Questions Learn more about Total Current Assets →
What does a Total Current Assets of MXN846.51 Mil mean?
Vistagen Therapeutics (MEX:VTGN) has a Total Current Assets of MXN846.51 Mil as of Mar. 2026. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Vistagen Therapeutics and its competitors.
Is Vistagen Therapeutics' Total Current Assets too high?
Vistagen Therapeutics' current Total Current Assets is MXN846.51 Mil. Overall, Vistagen Therapeutics has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does Vistagen Therapeutics' Total Current Assets compare to PSTV and KYNB?
Vistagen Therapeutics' Total Current Assets of MXN846.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Assets for a Biotechnology company?
A good Total Current Assets depends on the Biotechnology industry context. However, Total Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Assets mean?
A high Total Current Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets with liquidity less than one year as recorded on a company's balance sheet. View historical data for Vistagen Therapeutics and its competitors. Vistagen Therapeutics's current Total Current Assets is MXN846.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistagen Therapeutics stock overvalued right now?
Vistagen Therapeutics (MEX:VTGN) has a current Total Current Assets of MXN846.51 Mil. The stock's GF Value™ is MXN95.21, compared to a current price of MXN10.65 — trading 88.8% below its estimated fair value. The current Total Current Assets is MXN846.51 Mil. Vistagen Therapeutics' overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Assets calculated?
Total Current Assets is calculated from a company's financial statements. For Vistagen Therapeutics (MEX:VTGN), the current Total Current Assets is MXN846.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vistagen Therapeutics (MEX:VTGN) Overvalued in 2026?

Based on GuruFocus' analysis, Vistagen Therapeutics stock appears to be undervalued. The current stock price of MXN10.65 is trading 88.8% below its estimated GF Value™ of MXN95.21.

Key valuation signals for MEX:VTGN:

  • Total Current Assets: MXN846.51 Mil
  • GF Value™: MXN95.21 vs. price of MXN10.65 (88.8% below fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the MEX:VTGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vistagen Therapeutics Business Description

Other Exchanges VTGN:USA
Address 343 Allerton Avenue, South San Francisco, CA, USA, 94080
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
40GF Score

Get the complete analysis for MEX:VTGN

Total Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN10.65
Price
MXN95.21
GF Value